Trimel Pharmaceuticals Corporation Confirms No Corporate Developments
(firmenpresse) - TORONTO, ONTARIO -- (Marketwire) -- 02/09/12 -- Trimel Pharmaceuticals Corporation (TSX: TRL) (the "Company" or "Trimel") notes that, at the request of market surveillance on behalf of the Toronto Stock Exchange, Trimel is issuing this news release to confirm that there are no corporate developments, other than those that have been previously publicly disclosed, that would cause recent movements in the Company's share price.
About Trimel
Trimel Pharmaceuticals Corporation (TSX: TRL). Developing Medications for Female Sexual Health and conditions related to Aging, and Well Being. Trimel is developing multiple blockbuster product opportunities, including CompleoTRT, a no touch bioadhesive intranasal Testosterone gel for the treatment of male hypogonadism, a condition commonly referred to as "Low T". For more information, please visit .
Notice regarding forward-looking statements:
Information in this press release that is not current or historical factual information may constitute forward-looking information within the meaning of securities laws. Implicit in this information, are assumptions regarding our future operational results. These assumptions, although considered reasonable by the Company at the time of preparation, may prove to be incorrect. Readers are cautioned that actual performance of the Company is subject to a number of risks and uncertainties, and could differ materially from what is currently expected as set out above. For more exhaustive information on these risks and uncertainties you should refer to our final prospectus which is available at . Forward-looking information contained in this press release is based on our current estimates, expectations and projections, which we believe are reasonable as of the current date. You should not place undue importance on forward-looking information and should not rely upon this information as of any other date. While we may elect to, we are under no obligation and do not undertake to update this information at any particular time, whether as a result of new information, future events or otherwise, except as required by applicable securities law.
Contacts:
Trimel Pharmaceuticals Corporation
Kenneth G. Howling
Chief Financial Officer
416 679 0771
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 09.02.2012 - 21:03 Uhr
Sprache: Deutsch
News-ID 113158
Anzahl Zeichen: 0
contact information:
Town:
TORONTO, ONTARIO
Kategorie:
Healthcare
Diese Pressemitteilung wurde bisher 169 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Trimel Pharmaceuticals Corporation Confirms No Corporate Developments"
steht unter der journalistisch-redaktionellen Verantwortung von
Trimel Pharmaceuticals Corporation (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
